ADMA Biologics Inc - Common Stock (ADMA)

The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.

The financial landscape of 2026 has been defined by a seismic shift in capital allocation that few analysts predicted with such intensity. For the first time in over a decade, the long-dormant Russell 2000 index (NYSE Arca: IWM) is not just participating in a market rally—it is leading it.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ADMA To Contact Him Directly To Discuss Their Options

Short seller’s Characterization of ASCENIV’s Competitive Position Reflects Blatant Misunderstanding of ADMA’s Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and Therefore, May Not Respond to Vaccines

Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company’s possible violations of the federal securities laws.

ADMA Biologics, Inc. (NASDAQ: ADMA) shares are tumbling on Thursday as traders lean into risk-off positioning and punish weaker charts in a down tape. The Nasdaq is down 0.91% while the S&P 500 has shed 0.57%, and ADMA is moving with the broader market decline but with heavier downside pressure than the major indices.

Law Offices of Howard G. Smith announces an investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) on behalf of investors concerning the Company’s possible violations of federal securities laws.

RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today addressed a report issued on March 24, 2026 by Culper Research (the “Short Report”), a firm that has published similarly negative “research reports” regarding public companies after taking short positions in the stock. The Short Report discloses that Culper Research holds a short position in ADMA. ADMA, and its Board of Directors takes seriously its obligations to fairly and accurately report its operating and financial results and make all public disclosures in accordance with the rules and regulations of the U.S. Securities and Exchange Commission and in accordance with the standards of U.S. GAAP. The Short Report, by contrast, appears premised on speculative assertions derived from unidentified and unreliable sources and contains numerous misleading, false and inaccurate statements. Despite the conjecture pervading the Short Report, ADMA is taking appropriate steps to review the assertions.

Structure Therapeutics advances oral therapies for diabetes, obesity, and pulmonary disease through its clinical-stage drug pipeline.

RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”) agreement with JPMorgan Chase Bank, National Association (“JPMorgan”). The initiative underscores the Company’s strong financial position, durable free cash flow profile and confidence in its long-term growth trajectory.

ADMA Biologics (ADMA) Q4 2025 Earnings Transcript

FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth

Conference Call Scheduled for February 25, 2026, at 4:30 p.m. ET

This digital banking platform targets U.S. mass market consumers with mobile-first, fee-free services and strategic bank partnerships.

Solaris Energy Infrastructure delivers automation and logistics solutions to U.S. oil and gas operators using proprietary technologies.

Boot Barn Holdings operates over 500 stores nationwide, supplying western and workwear apparel to a diverse U.S. customer base.

FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance

RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Adam Grossman, President and Chief Executive Officer, will participate in a podium presentation at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 9:45 a.m. PT.

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

ADMA Biologics exemplifies GARP investing with strong revenue & earnings growth, high profitability, and a reasonable valuation relative to its biotech peers.